Provided by Tiger Fintech (Singapore) Pte. Ltd.

4D Molecular Therapeutics

4.24
-0.0700-1.62%
Post-market: 4.20-0.0400-0.94%16:47 EDT
Volume:196.32K
Turnover:828.08K
Market Cap:196.42M
PE:-1.34
High:4.34
Open:4.31
Low:4.13
Close:4.31
Loading ...

RBC Lowers Price Target on 4D Molecular Therapeutics to $35 From $39, Keeps Outperform, Speculative Risk

MT Newswires Live
·
03 Mar

Promising Developments in 4D Molecular Therapeutics’ Gene Therapy Program Justify Buy Rating

TIPRANKS
·
03 Mar

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alcon (ALC) and Cooper Co (COO)

TIPRANKS
·
03 Mar

4D Molecular Therapeutics Inc : RBC Cuts Target Price to $35 From $39

THOMSON REUTERS
·
03 Mar

4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations

Simply Wall St.
·
02 Mar

4D Molecular Therapeutics Reports Strong Clinical Progress and Financial Position

TIPRANKS
·
02 Mar

4D Molecular Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
01 Mar

4D Molecular Therapeutics FY 2024 GAAP EPS $(2.98) Misses $(2.92) Estimate, Sales $37.000K

Benzinga
·
01 Mar

Chardan Lowers Price Target on 4D Molecular Therapeutics to $30 From $39, Keeps Buy Rating

MT Newswires Live
·
11 Feb

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Globus Medical (GMED) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
11 Feb

Analysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
11 Feb

4D Molecular price target lowered to $30 from $39 at Chardan

TIPRANKS
·
11 Feb

Chardan Capital Keeps Their Buy Rating on 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
11 Feb

4D Molecular Therapeutics (FDMT) Gets a Buy from RBC Capital

TIPRANKS
·
11 Feb

4D Molecular’s wAMD drug is best-in-class, says RBC, sees ‘ideal’ entry point

TIPRANKS
·
11 Feb

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

GlobeNewswire
·
29 Jan

H.C. Wainwright Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
22 Jan

BUZZ-BMO downgrades 4D Molecular Therapeutics to 'market perform' on durability concerns

Reuters
·
14 Jan

BMO Capital Downgrades 4D Molecular Therapeutics to Market Perform From Outperform, Adjusts Price Target to $15 From $40

MT Newswires Live
·
13 Jan

4D Molecular Therapeutics Price Target Maintained With a $36.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Jan